Search - tctmd.com

Displaying 361 - 380 of 970

Sort: Relevancy | Date

News Daily News

Guideline-Directed Therapies Underused in Frail HF Patients

L.A. McKeown

March 11, 2022

News Daily News

Skipping Low-Value Cardiovascular Care Could Save Billions: AHA

Michael O'Riordan

March 01, 2022

News Opinion CV Team Dispatch

March 2022 News Roundup

L.A. McKeown

March 01, 2022

News Daily News

Recurrent Stroke Risk Lower With More Intense LDL-Lowering: Meta-analysis

Yael L. Maxwell

March 01, 2022

News Daily News

Fewer Diabetic Complications Seen When NOACs Given for AF

L.A. McKeown

February 22, 2022

News Daily News

Statin Intolerance Overestimated—Only ‘Small Number’ Get Side Effects: Meta-analysis

Michael O'Riordan

February 18, 2022

News Daily News

No Increased Bleeding With Alteplase in Stroke Patients on DOACs: Registry Data

Yael L. Maxwell

February 15, 2022

News Daily News

Homozygous FH Diagnosis Often Comes Late, With Lackluster Care

Michael O'Riordan

February 10, 2022

News Conference News ISC 2022

ACTION-CVT: DOACs Look Like a Good Option for Cerebral Venous Thrombosis

Todd Neale

February 10, 2022

News Daily News

Acetaminophen Raises BP, Just Like NSAIDs Do, in Patients With Hypertension

Yael L. Maxwell

February 09, 2022

News Opinion CV Team Dispatch

February 2022 News Roundup

L.A. McKeown

February 01, 2022

News Daily News

In the US, HF Prevalence—and Costs—Rising Steeply: HFSA Report

Michael O'Riordan

January 27, 2022

News Daily News

Optimal Medical Therapy for Stable Angina: Which Drugs? How Long?

Michael O'Riordan

January 25, 2022

News Daily News

DOACs Should Be Standard to Prevent VTE Recurrence in Cancer: Meta-analysis

L.A. McKeown

January 20, 2022

News Features

Pricey Inclisiran Is Rolling Out: a ‘Buy-and-Bill’ Model May Smooth Its Path

Michael O'Riordan

January 17, 2022

News Daily News

As US Diabetes Rates Soar, AHA Urges CV Risk Factor Control

Caitlin E. Cox

January 10, 2022

News Daily News

MICHELLE Published: Low-Dose Rivaroxaban Cuts VTE Risk After COVID-19 Admission

Todd Neale

December 29, 2021

News Daily News

Apixaban Appears Safer, More Effective Than Rivaroxaban in Medicare Study

Todd Neale

December 27, 2021

News Features

FFR’s Future: Negative Trials Spur Debate Over Technology’s Role

Michael O'Riordan

December 23, 2021

News Daily News

Upping Generic CV Drug Scripts Could Save Medicare and Patients Millions

L.A. McKeown

December 17, 2021

Advertisement

Guideline-Directed Therapies Underused in Frail HF Patients

Skipping Low-Value Cardiovascular Care Could Save Billions: AHA

March 2022 News Roundup

Recurrent Stroke Risk Lower With More Intense LDL-Lowering: Meta-analysis

Fewer Diabetic Complications Seen When NOACs Given for AF

Statin Intolerance Overestimated—Only ‘Small Number’ Get Side Effects: Meta-analysis

No Increased Bleeding With Alteplase in Stroke Patients on DOACs: Registry Data

Homozygous FH Diagnosis Often Comes Late, With Lackluster Care

ACTION-CVT: DOACs Look Like a Good Option for Cerebral Venous Thrombosis

Acetaminophen Raises BP, Just Like NSAIDs Do, in Patients With Hypertension

February 2022 News Roundup

In the US, HF Prevalence—and Costs—Rising Steeply: HFSA Report

Optimal Medical Therapy for Stable Angina: Which Drugs? How Long?

DOACs Should Be Standard to Prevent VTE Recurrence in Cancer: Meta-analysis

Pricey Inclisiran Is Rolling Out: a ‘Buy-and-Bill’ Model May Smooth Its Path

As US Diabetes Rates Soar, AHA Urges CV Risk Factor Control

MICHELLE Published: Low-Dose Rivaroxaban Cuts VTE Risk After COVID-19 Admission

Apixaban Appears Safer, More Effective Than Rivaroxaban in Medicare Study

FFR’s Future: Negative Trials Spur Debate Over Technology’s Role

Upping Generic CV Drug Scripts Could Save Medicare and Patients Millions

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content